Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dynavox Group ABFRA:H3Q -0.60%82 EV-to-EBIT is 26.29 as of Sep. 02, 2026, which is 34% below its 10-year median of 39.74. GuruFocus rates FRA:H3Q with a GF Score™ of 82/100 and a GF Value™ of €7.86 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Dynavox Group AB ranks worse than 67.3% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dynavox Group AB's Enterprise Value for the quarter that ended in Jun. 2026 was €662.8 Mil.
Dynavox Group AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €30.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavox Group AB EV-to-EBIT Related Terms
Dynavox Group AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Dynavox Group AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's EV-to-EBIT falls into.
Dynavox Group AB's current Enterprise Value is €790.2 Mil.
Dynavox Group AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €30.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavox Group AB (FRA:H3Q) has a EV-to-EBIT of 26.29 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dynavox Group AB and its competitors. This is 34% below median its historical median of 39.74. Over the past decade, Dynavox Group AB's EV-to-EBIT has ranged from 23.44 to 65.55. According to the industry distribution chart, Dynavox Group AB ranks #319 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 67.3%.
Is Dynavox Group AB's EV-to-EBIT too high?
Dynavox Group AB's current EV-to-EBIT of 26.29 is 34% below median its 10-year median of 39.74. Over the past 10 years, this metric has ranged from a low of 23.44 to a high of 65.55. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Dynavox Group AB's value of 26.29 is 40.6% above this industry median. Based on the distribution chart, Dynavox Group AB ranks #319 out of 474 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Dynavox Group AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #319 out of 474 companies for EV-to-EBIT. This places Dynavox Group AB in the lower half of its industry. The industry median EV-to-EBIT is 18.70. Dynavox Group AB's value of 26.29 is 40.6% above this benchmark. Historically, Dynavox Group AB's own EV-to-EBIT has ranged from 23.44 to 65.55 over the past decade. While the company's 10-year median is 39.74 vs. the industry median of 18.70, Dynavox Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current EV-to-EBIT of 26.29 is 40.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dynavox Group AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current EV-to-EBIT is 26.29, which is 34% below median its own 10-year median of 39.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (FRA:H3Q) is currently considered Modestly Undervalued. The stock's GF Value™ is €7.86, compared to a current price of €6.66 — trading 15.3% below its estimated fair value. The current EV-to-EBIT is 26.29, which is 34% below median its 10-year median of 39.74 and 40.6% above the Medical Devices & Instruments industry median of 18.70. Dynavox Group AB's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dynavox Group AB (FRA:H3Q), the current EV-to-EBIT is 26.29 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (FRA:H3Q) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of €6.66 is trading 15.3% below its estimated GF Value™ of €7.86.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for FRA:H3Q:
EV-to-EBIT: 26.29 (34% below median its 10-year median of 39.74)
GF Value™: €7.86 vs. price of €6.66 (15.3% below fair value)
Industry Position: 40.6% above the Medical Devices & Instruments median (#319 of 474)
No single metric tells the full story. See the FRA:H3Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
82GF Score
Get the complete analysis for FRA:H3Q
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3Q has been successfully added to your 
